8-K: Centene Announces Positive Impact from 2023 Risk Adjustment, Reaffirms 2024 EPS Guidance

Centene reports a $0.7 billion net outperformance from the final 2023 risk adjustment, leading to increased 2024 earnings estimates.

Summary

• Centene has announced a positive adjustment to its financials due to the final risk adjustment transfers for the 2023 benefit year published by the Centers for Medicare and Medicaid Services (CMS).
• The company initially recorded a $1.3 billion net risk adjustment payable as of March 31, 2024.
• The final CMS risk adjustment resulted in a $0.0 billion receivable, leading to a $1.3 billion difference.
• After accounting for an increase in the Minimum Medical Loss Ratio (MLR) payable and other offsets, Centene recorded a net outperformance of $0.7 billion in Q2 2024.
• This outperformance will increase the minimum MLR payable for the 2024 benefit year by approximately $0.1 billion, impacting the second half of 2024.
• The net outperformance for risk adjustment for the full year 2024 is estimated to be $0.6 billion.
• Centene expects to report GAAP diluted earnings per share (EPS) of $2.16 and adjusted diluted EPS of $2.42 for the second quarter of 2024, inclusive of the risk adjustment outperformance.
• The company reaffirms its 2024 full year GAAP diluted EPS guidance floor of greater than $5.94 and adjusted diluted EPS guidance floor of greater than $6.80.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant outperformance from the risk adjustment and the reaffirmation of full-year earnings guidance. The company's ability to manage risk effectively is a positive sign for investors.

Positives

• The final 2023 risk adjustment resulted in a significant $0.7 billion net outperformance for Centene.
• The company's second quarter earnings per share are positively impacted by the risk adjustment outperformance.
• Centene has reaffirmed its full-year earnings guidance, indicating confidence in its financial outlook.
• The company's ability to manage risk adjustments effectively has resulted in a positive financial outcome.

Negatives

• The minimum MLR payable for the 2024 benefit year will increase by approximately $0.1 billion, impacting the second half of 2024.
• The company's actual results for the second quarter of 2024 may differ from the preliminary estimates provided.

Risks

• The company's future performance is subject to various risks and uncertainties, including changes in healthcare practices, regulations, and market conditions.
• There are risks associated with the company's ability to accurately predict and manage health benefits and other operating expenses.
• The company faces competition in the healthcare industry, which could impact its financial results.
• The company's financial results could be affected by changes in government healthcare programs and regulations.
• The company's ability to maintain or achieve improvement in CMS Star ratings can impact revenue and future growth.

Future Outlook

Centene expects to reaffirm its 2024 full year GAAP diluted EPS guidance floor of greater than $5.94 and adjusted diluted EPS guidance floor of greater than $6.80 on its second quarter 2024 earnings call.

Management Comments

• The company believes that non-GAAP financial measures are helpful in allowing investors to more accurately assess the ongoing nature of the company's operations.
• Management uses non-GAAP financial measures internally in evaluating the company's performance and for planning purposes.

Industry Context

This announcement is significant in the healthcare industry as it highlights the impact of risk adjustment programs on managed care companies' financial performance. The positive adjustment for Centene could be seen as a sign of effective risk management and operational efficiency compared to its peers.

Comparison to Industry Standards

• Centene's positive risk adjustment outcome contrasts with some competitors who may have faced challenges in managing risk adjustments, as indicated by the 'Estimated other offsets primarily resulting from competitor inability to pay into the CMS risk adjustment program'.
• The company's reaffirmation of its EPS guidance is a positive signal, especially in a sector where regulatory changes and healthcare costs can significantly impact profitability.
• Other large healthcare providers such as UnitedHealth Group (UNH) and Humana (HUM) also face similar risk adjustment challenges, and their results are closely watched by investors to gauge industry trends.

Stakeholder Impact

• Shareholders will likely react positively to the increased earnings and reaffirmed guidance.
• Employees may benefit from the company's improved financial performance.
• Customers may see improved services and stability due to the company's financial health.
• Creditors may view the company as a lower risk due to its positive financial results.

Next Steps

• Centene will provide additional detail on its second quarter 2024 earnings call on Friday, July 26, 2024.
• The company will continue to monitor and manage its risk adjustment programs.

Key Dates

Keywords

risk adjustment, earnings per share, EPS, Medicare, Medicaid, financial results, healthcare, CMS, MLR, outperformance